Zenas BioPharma Files Annual Proxy Statement
Ticker: ZBIO · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1953926
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Zenas BioPharma filed its proxy statement for the June 10th annual meeting. Vote your shares!
AI Summary
Zenas BioPharma, Inc. filed a DEF 14A proxy statement on April 28, 2025, for its annual meeting on June 10, 2025. The filing concerns the company's governance and shareholder matters. Zenas BioPharma, Inc. is a pharmaceutical preparations company incorporated in Delaware.
Why It Matters
This filing provides shareholders with crucial information regarding the company's annual meeting, including details on voting matters and corporate governance, enabling informed participation.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures.
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Registrant
- 0001104659-25-039765 (filing_id) — Accession Number
- 20250428 (date) — Filing Date
- 20250610 (date) — Meeting Date
- 0001953926 (company_id) — Central Index Key
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is filed by a company to solicit shareholder votes for its annual meeting, providing details on matters to be voted upon and corporate governance.
When is the Zenas BioPharma, Inc. annual meeting scheduled?
The annual meeting for Zenas BioPharma, Inc. is scheduled for June 10, 2025.
What is the filing date of this proxy statement?
This DEF 14A proxy statement was filed on April 28, 2025.
What is the primary business of Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. operates in the Pharmaceutical Preparations industry, SIC code 2834.
Where is Zenas BioPharma, Inc. headquartered?
Zenas BioPharma, Inc. is headquartered at 852 Winter Street, Suite 250, Waltham, MA 02451.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Zenas BioPharma, Inc. (ZBIO).